Topic Hub
24 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 24 of 24 clinical reviews.
Does Prolia (denosumab) affect appetite or cravings? A clinician-level review of the FREEDOM trial data, FDA adverse-event records, RANK/RANKL biology, and practical management steps for patients on denosumab.
Read clinical reviewA clinician-level review of denosumab (Prolia) use in patients with autoimmune disease: mechanism, immunological risks, drug interactions, monitoring protocols, and guidance from FREEDOM and post-marketing data.
Read clinical reviewA physician-reviewed, evidence-based guide to how denosumab (Prolia) affects bone mineral density, fracture risk, and long-term skeletal outcomes. Includes FREEDOM trial data, dosing, discontinuation risks, and clinical decision frameworks.
Read clinical reviewA board-reviewed, primary-literature analysis of the cancer risk signals associated with denosumab (Prolia), covering FREEDOM trial data, FDA labeling updates, post-marketing surveillance, and clinical decision-making guidance for prescribers.
Read clinical reviewA physician-reviewed, evidence-based analysis of denosumab's long-term cardiovascular effects, covering atrial fibrillation, hypocalcemia-related arrhythmia, MACE data, and what clinicians need to monitor in practice.
Read clinical reviewA physician-reviewed deep-dive into denosumab (Prolia) and cognition: RANKL biology, FREEDOM trial data, pharmacovigilance signals, and clinical decision-making for patients concerned about brain fog or cognitive decline.
Read clinical reviewA physician-reviewed comparison of compounded denosumab versus branded Prolia, covering efficacy data, safety profiles, regulatory status, cost, and clinical decision-making for osteoporosis treatment.
Read clinical reviewA physician-level review of denosumab (Prolia) evidence graded by GRADE methodology, covering fracture reduction, bone density, and safety across key RCTs including FREEDOM, FREEDOM Extension, and current AACE/Endocrine Society guidelines.
Read clinical reviewA clinical deep-dive into denosumab-associated dermatologic adverse effects, including eczema, cellulitis, alopecia, and rash, with primary-literature citations and practical management guidance.
Read clinical reviewA comprehensive, physician-reviewed guide to how denosumab (Prolia) affects liver function, including hepatotoxicity risk, lab monitoring, mechanism of action, and clinical trial data from FREEDOM and post-marketing surveillance.
Read clinical reviewA clinician-level review of denosumab (Prolia) and its effects on mental health, mood, depression, and neuropsychiatric symptoms. Includes trial data, mechanism analysis, and prescribing guidance.
Read clinical reviewA clinician-level review of how denosumab affects bone metabolism, RANKL-OPG signaling, energy expenditure, and body composition, with primary-literature citations from FREEDOM and beyond.
Read clinical reviewA physician-level review of denosumab (Prolia) dosing, the absence of validated microdosing protocols, fracture-risk rebound data, and what clinicians should do instead.
Read clinical reviewAn MD/PharmD-level review of how denosumab (Prolia) affects skeletal muscle, what the FREEDOM trial and downstream research revealed, and evidence-based strategies to preserve or build muscle during RANK-L inhibition therapy.
Read clinical reviewMD/PharmD-level guide to diagnosing and managing BMD plateau and non-response on denosumab (Prolia): secondary causes, lab workup, dose timing, combination therapy, and when to switch agents.
Read clinical reviewA clinician-level guide to using denosumab (Prolia) after bariatric surgery, covering fracture risk, calcium repletion, FREEDOM trial data, dosing, and monitoring protocols.
Read clinical reviewA comprehensive clinical guide to the denosumab pre-surgery hold window, covering fracture rebound risk, optimal timing, bridging strategies, and evidence-based protocols for perioperative management of Prolia patients.
Read clinical reviewStopping Prolia (denosumab) triggers rapid, severe bone loss and vertebral fracture risk within 7 to 12 months. This MD-level guide covers the rebound mechanism, fracture data, transition protocols, and clinical decision frameworks.
Read clinical reviewA clinician-level review of denosumab (Prolia) and kidney function: evidence from FREEDOM and post-marketing data on hypocalcemia risk, CKD dosing, and who benefits most.
Read clinical reviewA clinical guide to denosumab (Prolia) seasonal administration timing, rebound fracture risk, dosing intervals, and practical scheduling strategies for clinicians and patients.
Read clinical reviewA clinician-level review of denosumab's (Prolia) effects on sexual function, covering hormonal pathways, trial data from FREEDOM and related studies, and practical guidance for patients and prescribers.
Read clinical reviewA clinician-level review of how denosumab (Prolia) may affect sleep architecture, RANKL signaling in the CNS, bone-pain relief and its downstream effects on sleep quality, and what patients and prescribers need to know.
Read clinical reviewA clinician-level guide to safely restarting denosumab (Prolia) after acute illness, covering the rebound fracture risk, timing windows, bridging strategies, and current guideline recommendations.
Read clinical reviewA week-by-week clinical guide to the first month on Prolia (denosumab): injection-site reactions, bone-marker changes, calcium monitoring, and what your first 30 days actually look like based on FREEDOM and post-marketing data.
Read clinical review